Adverse effects of CABG treatment were retrieved from previously published randomized controlled trials. The probability of hazardous events (HE) was retrieved from eleven different trials shown in table S2. The definition of restenosis in the case of CABG is not straightforward, it could refer to reduced patency in the grafted vessel due to atherosclerosis or to a previously untreated lesion upstream of the original lesion. Here, we assumed the first definition and estimated P (Restenosis|CABG) to be 1.9% [4] .
Patient Characteristics
From a total of 2,733 interventions, we excluded 913 interventions due to missing angiographic follow-up. Categorical variables were summarized by absolute counts and relative proportions and were compared with Fisher's exact test. Continuous variables were summarized by mean and standard deviation and compared using Welch's t-test.
Adverse Effects for Coronary Artery Bypass Grafting
Adverse effects of CABG treatment were retrieved from previously published randomized controlled trials. The probability of hazardous events (HE) was retrieved from eleven different trials shown in table S2. The definition of restenosis in the case of CABG is not straightforward, it could refer to reduced patency in the grafted vessel due to atherosclerosis or to a previously untreated lesion upstream of the original lesion. Here, we assumed the first definition and estimated P (Restenosis|CABG) to be 1.9% [4] . 
Subgroups
Due to a smaller amount of data available for angiographic restenosis, a smaller number of subgroups was used, compared to the analyses considering clinical restenosis. Owing to insufficient data, our evaluation did not cover females younger than 60 years of age. In addition, for endpoints after 1 year, we could not factor in diabetics younger than 60 years old, and for angiographic restenosis we could not account for diabetic females older than 60 years of age. However, patients specific to these subgroups were part of supersets of these subgroups and therefore still included in the analyses, for instance females younger than 60 years are part of females of any age. Restenosis  Angiographic 133  157  133  185  Clinical 148  157  148  185   Table S3 : Number of subgroups generated for four different analyses. Bare-metal stent subgroups (BMS) were used to train classifiers to predict the probability of restenosis, and drug-eluting stent subgroups (DES) were used to predict hazardous events (HE). Table S5 : Excluded subgroups due to insufficient data for prediction of angiographic and clinical restenosis, and 3-year hazardous events. In total 6 subgroups were excluded. Asterisks indicate all three subgroups for this particular group, e.g. all genders, male and female.
1-yr HE 3-yr HE BMS DES BMS DES

Costs
The costs were estimated based on Medicare reimbursements to hospitals in the U.S. for the year 2013 [1] . Costs are based on full update national adjusted operating standardized amounts and capital standard federal rate averaged across all urban and rural areas. Table S7 : Estimated probabilities of adverse effects for angiographic restenosis and 1-year and 3-year hazardous events analysis, respectively, without constructing subgroup-specific classifiers. Baseline refers to treatment exclusively with drug-eluting stents and costs are in 2013 U.S. dollar.
